fbpx

molecules of the month

GS-9876 (lanraplenib)

SYK-selective kinase inhibitor

oral, completed Ph. I in HV

from optimization of prior candidate

ACS Med. Chem. Lett. Feb. 12, 2020

Gilead Sciences, Seattle, WA

GS-9876 (lanraplenib)
1 min read

GS-9876 (lanraplenib) (Gilead Sciences oral SYK selective kinase inhibitor clinical candidate)


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: